CN113444171A - 金黄色葡萄球菌α-毒素特异性抗体及其应用 - Google Patents

金黄色葡萄球菌α-毒素特异性抗体及其应用 Download PDF

Info

Publication number
CN113444171A
CN113444171A CN202010663921.1A CN202010663921A CN113444171A CN 113444171 A CN113444171 A CN 113444171A CN 202010663921 A CN202010663921 A CN 202010663921A CN 113444171 A CN113444171 A CN 113444171A
Authority
CN
China
Prior art keywords
antibody
amino acid
ser
seq
substantially similar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010663921.1A
Other languages
English (en)
Chinese (zh)
Inventor
赵子渊
张瀞文
曹一孚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xingmeng Biomedical Suzhou Co ltd
Original Assignee
Xingmeng Biomedical Suzhou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xingmeng Biomedical Suzhou Co ltd filed Critical Xingmeng Biomedical Suzhou Co ltd
Publication of CN113444171A publication Critical patent/CN113444171A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
    • G01N2333/3156—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae [Pneumococcus]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN202010663921.1A 2020-03-25 2020-07-10 金黄色葡萄球菌α-毒素特异性抗体及其应用 Pending CN113444171A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062994744P 2020-03-25 2020-03-25
US62/994,744 2020-03-25

Publications (1)

Publication Number Publication Date
CN113444171A true CN113444171A (zh) 2021-09-28

Family

ID=75223147

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202010663921.1A Pending CN113444171A (zh) 2020-03-25 2020-07-10 金黄色葡萄球菌α-毒素特异性抗体及其应用
CN202010664920.9A Pending CN113444173A (zh) 2020-03-25 2020-07-10 金黄色葡萄球菌α-毒素特异性抗体及其应用
CN202010664832.9A Pending CN113444172A (zh) 2020-03-25 2020-07-10 金黄色葡萄球菌α-毒素特异性抗体及其应用
CN202110321155.5A Active CN113444174B (zh) 2020-03-25 2021-03-25 金黄色葡萄球菌α-毒素特异性抗体及其应用

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202010664920.9A Pending CN113444173A (zh) 2020-03-25 2020-07-10 金黄色葡萄球菌α-毒素特异性抗体及其应用
CN202010664832.9A Pending CN113444172A (zh) 2020-03-25 2020-07-10 金黄色葡萄球菌α-毒素特异性抗体及其应用
CN202110321155.5A Active CN113444174B (zh) 2020-03-25 2021-03-25 金黄色葡萄球菌α-毒素特异性抗体及其应用

Country Status (8)

Country Link
US (1) US11530256B2 (enExample)
EP (1) EP3895762A3 (enExample)
JP (1) JP7765191B2 (enExample)
KR (1) KR20210119913A (enExample)
CN (4) CN113444171A (enExample)
BR (1) BR102021005680A2 (enExample)
SG (1) SG10202103015VA (enExample)
TW (1) TWI877334B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115785281A (zh) * 2022-09-27 2023-03-14 兴盟生物医药(苏州)有限公司 含有狂犬病病毒g蛋白的融合蛋白的制备方法及应用
WO2023208123A1 (zh) * 2022-04-28 2023-11-02 珠海泰诺麦博制药股份有限公司 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117771379B (zh) * 2023-10-25 2024-08-30 珠海泰诺麦博制药股份有限公司 特异性结合金黄色葡萄球菌Hla毒素的全人源抗体与抗生素的组合

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP2284193A1 (en) 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
MX375113B (es) 2011-02-08 2025-03-04 Medimmune Llc Anticuerpos que se unen específicamente a la toxina alfa de staphylococcus aureus y métodos de uso.
WO2013013323A1 (en) 2011-07-28 2013-01-31 Cangene Corporation Staphlococcus aureus alpha-hemolysin antibodies
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
BR112016008275A2 (pt) * 2013-10-17 2017-10-03 Arsanis Biosciences Gmbh Anticorpo com reatividade cruzada ao staphylococcus aureus, preparações farmacêuticas ou para diagnóstico compreendendo o anticorpo, anticorpo para uso médico e para diagnóstico, um ácido nucleico isolado que codifica o anticorpo, plasmideo ou cassete de expressao, e célula hospedeira compreendendo tal plasmideo ou cassete de expressao, método para produzir o anticorpo usando tal célula hospedeira, método para produzir variantes de anticorpos, um cristal formado por um monômero da hla ou lukd com dito anticorpo, um paratopo isolado do anticorpo, o epítopo isolado e uma molécula de ligação ligando especificamente ao dito epítopo, um método de triagem para identificar um ligante que se liga ao dito epítopo, um imunógeno compreendendo dito epítopo, e dito imunógeno usado para induzir uma resposta imune protetora
WO2016044588A1 (en) 2014-09-19 2016-03-24 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
MA41613A (fr) * 2015-02-23 2018-01-02 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
CN109384844B (zh) 2017-08-04 2020-12-18 中国人民解放军军事医学科学院基础医学研究所 一种抗金黄色葡萄球菌α溶血素单克隆抗体及应用
CN109400704B (zh) 2018-11-14 2020-07-21 珠海泰诺麦博生物技术有限公司 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用
CN109705213B (zh) * 2018-12-04 2023-04-18 上海长征医院 抗金黄色葡萄球菌毒素抗体及其用途
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
CN110437334B (zh) 2019-07-26 2020-12-01 西南医科大学 全人源抗金黄色葡萄球菌α-溶血素重组抗体

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023208123A1 (zh) * 2022-04-28 2023-11-02 珠海泰诺麦博制药股份有限公司 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体
CN117106077A (zh) * 2022-04-28 2023-11-24 珠海泰诺麦博制药股份有限公司 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体
CN115785281A (zh) * 2022-09-27 2023-03-14 兴盟生物医药(苏州)有限公司 含有狂犬病病毒g蛋白的融合蛋白的制备方法及应用

Also Published As

Publication number Publication date
EP3895762A3 (en) 2022-01-12
CN113444173A (zh) 2021-09-28
JP7765191B2 (ja) 2025-11-06
KR20210119913A (ko) 2021-10-06
JP2021155416A (ja) 2021-10-07
EP3895762A2 (en) 2021-10-20
US20210317193A1 (en) 2021-10-14
US11530256B2 (en) 2022-12-20
BR102021005680A2 (pt) 2022-03-08
TWI877334B (zh) 2025-03-21
CN113444174B (zh) 2025-11-28
SG10202103015VA (en) 2021-10-28
CN113444174A (zh) 2021-09-28
TW202202519A (zh) 2022-01-16
CN113444172A (zh) 2021-09-28

Similar Documents

Publication Publication Date Title
US20230340133A1 (en) Antibodies Directed Against CD127
JP7057843B2 (ja) ＧＵＣＹ２ｃに特異的な抗体及びその使用
US9758586B2 (en) Chimeric rabbit/human ROR1 antibodies
JP6797111B2 (ja) イヌｐｄ−ｌ１と結合するｐｄ−ｌ１抗体
EP3712170A1 (en) Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof
CN110267989B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
KR20210099027A (ko) 항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도
US20250136668A1 (en) Antibody specific to spike protein of sars-cov-2 and uses thereof
CN113444174B (zh) 金黄色葡萄球菌α-毒素特异性抗体及其应用
CN112672788A (zh) 抗金黄色葡萄球菌凝集因子a(clfa)的抗体
US20230192861A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
KR20230017226A (ko) Cd40 결합 단백질
KR102231685B1 (ko) 인간 항-il-32 항체
US20240075158A1 (en) Complex of anti-il-4r antibody or antigen-binding fragment thereof and medical use thereof
KR20210126641A (ko) 보체 및 표적 항원에 결합하기 위해 이중 특이적 항체를 사용하는 조성물 및 방법
CN113416249B (zh) 针对破伤风毒素的组合物
KR20230158058A (ko) 시알산-결합 ig-유사 렉틴 15에 특이적인 항체 및 이의 용도
KR20250114286A (ko) 개과 악성종양에 대한 면역제
KR20210158693A (ko) 항 ｐｃｓｋ９ 항체 및 이의 용도
HK40051457A (en) Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210928

WD01 Invention patent application deemed withdrawn after publication